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OBJECTIVE: To assess clinical and laboratory features that differentiate acute lymphoblastic leukemia from systemic
juvenile idiopathic arthritis at disease onset.
METHODS: Fifty-seven leukemia patients with musculoskeletal involvement, without blasts on peripheral blood and
without glucocorticoid therapy at disease onset and 102 systemic juvenile idiopathic arthritis patients (International
League of Associations for Rheumatology criteria) were retrospectively evaluated. The following features were
examined: fever, rheumatoid rash, arthritis, limb pain, hepatomegaly, splenomegaly, pericarditis, myocarditis,
pleuritis, weight loss, bleeding, anemia, leukopenia, neutropenia, thrombocytopenia, erythrocyte sedimentation
rate, and lactic dehydrogenase levels.
RESULTS: The median age at disease onset was significantly higher in leukemia patients than in those with systemic-
onset juvenile idiopathic arthritis (5.8 vs. 3.8 years). In addition, the frequencies of limb pain, hepatomegaly, weight
loss and hemorrhagic manifestations were significantly higher in leukemia patients than in systemic-onset juvenile
idiopathic arthritis patients (70% vs. 1%, 54% vs. 32%, 30% vs. 8%, and 9% vs. 0%, respectively). Likewise, the
frequencies of anemia, leukopenia, neutropenia, thrombocytopenia and high lactic dehydrogenase levels were
statistically higher in leukemia patients than in patients with systemic-onset juvenile idiopathic arthritis (88% vs.
57%, 39% vs. 1%, 60% vs. 1%, 77% vs. 1%, and 56% vs. 14%, respectively). Remarkably, multivariate analysis
revealed that limb pain (OR=553; 95% CI=46.48-6580.42) and thrombocytopenia (OR=754.13; 95% CI=64.57-
8806.72) were significant independent variables that differentiated leukemia from systemic-onset juvenile
idiopathic arthritis. The R2 of the Nagelkerke test was 0.91, and the Kaplan-Meier survival curves were similar for
acute lymphoblastic leukemia patients with and without limb pain.
CONCLUSION: Our study emphasizes the importance of investigating leukemia in patients presenting with
musculoskeletal manifestations and, in particular, limb pain associated with thrombocytopenia.
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INTRODUCTION
Acute lymphoblastic leukemia is the most prevalent
cancer in children and adolescents
1,2 and is the most
frequent malignant neoplasm associated with musculoske-
letal complaints at disease onset.
3-9 The main clinical
osteoarticular manifestations in early leukemia include limb
pain, nighttime pain, arthralgia, and arthritis.
4-9 Moreover,
pediatric leukemia may develop clinical features and
laboratory alterations that mimic rheumatic diseases, in
particular systemic-onset juvenile idiopathic arthritis (also
known as juvenile rheumatoid arthritis).
7,10,11
Approximately 4-41% of children and adolescents with
juvenile idiopathic arthritis (JIA) have systemic-onset JIA
(SoJIA).
12,13 This disease subtype is defined as the presence
of arthritis in one or more joints associated with a daily fever
above 39˚C for a minimum period of 15 days and with the
presence of at least one of the following manifestations:
rheumatoid rash, generalized adenomegaly, pericarditis,
pleuritis, hepatomegaly, and/or splenomegaly.
14
To our knowledge, there are few studies that have
evaluated the differences between acute leukemia and
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10,11 Ostrov et al
10 showed that
musculoskeletal pain causing nighttime wakening was
more prevalent in eight leukemia and two acute nonlym-
phocytic leukemia patients vs. 10 patients with a systemic
subtype. Jones et al
11 compared leukemia vs. JIA patients
and demonstrated a high sensitivity and specificity of the
combination of hematological abnormalities and nighttime
pain for a leukemia diagnosis. In their study, however, the
three most important JIA subtypes (oligoarthritis, polyar-
thritis, and systemic) were included, and only 20% of the
patients had SoJIA. Furthermore, these two studies did not
describe any other relevant alterations at disease onset, for
example, hemorrhagic manifestations, macrophage activa-
tion syndrome (MAS), pericarditis, myocarditis, or neutro-
penia. Finally, a multivariate analysis was not performed in
either study.
Therefore, we aimed to assess the initial clinical and
laboratory features that differentiate leukemia from SoJIA.
Kaplan-Meier survival curves in leukemia patients with and
without limb pain were also evaluated.
METHODS AND MATERIALS
The study period took place from August 1996 to October
2010. During this period, 57 consecutive children and
adolescents suffering from leukemia with musculoskeletal
manifestations but without blasts on peripheral blood smear
or glucocorticoid therapy were selected from a population
of 190 patients who had complete medical records (the total
population of leukemia patients was 285). In addition, 102
consecutive SoJIA patients who did not receive initial
glucocorticoid therapy and who had complete medical
records were selected from a total population of 136 SoJIA
patients. Leukemia and SoJIA patients were retrospectively
studied according to their initial clinical and laboratory
features. All of the patients were evaluated by a pediatric
oncologist and/or a pediatric rheumatologist at our uni-
versity hospital.
The definitive diagnosis of leukemia was established
according to the presence of at least 25% blasts on a bone
marrow smear, and all of the slides were reviewed by an
expert cytologist. Arthritis was diagnosed according to the
International League of Associations for Rheumatology
(ILAR) criteria.
14 The Local Ethics Committee of our
hospital approved this study.
The initial clinical manifestations and laboratory altera-
tions were evaluated for leukemia and SoJIA patients. The
presence of the following initial clinical manifestations
were systematically analyzed: fever (axillary temperature
$37.8˚C), rheumatoid rash (erythematous, macular, non-
pruritic, and evanescent salmon-colored lesions most
commonly over the trunk and proximal limbs), generalized
lymph node enlargement, hepatomegaly (liver edge .2c m
above the right costal margin), splenomegaly (palpable
spleen), pericarditis and myocarditis (confirmed by Doppler
echocardiography), pleuritis (confirmed by thorax radio-
graphy and/or thorax ultrasound), weight loss (.2k gi n
one month) and bleeding (gingival bleeding, petechiae,
ecchymosis, and/or epistaxis).
13
Musculoskeletal manifestations were defined as the
presence of arthralgia (joint pain or tenderness without
evidence of inflammation), arthritis (swelling within a joint
or a limitation in the range of joint movement with joint pain
or tenderness),
14 subjective complaints of limb pain (bone
pain, tenderness or other discomfort in one or more limbs
without evidence of inflammation), and nighttime pain
(musculoskeletal pain causing nocturnal wakening).
The following peripheral blood alterations were system-
atically evaluated: anemia (,10 g/dl), leukopenia (,4,000/
mm
3), leukocytosis (.12,000/mm
3), neutropenia (,1,000/
mm
3), thrombocytopenia (,150,000/mm
3) and thrombocy-
tosis (.400,000/mm
3). The erythrocyte sedimentation rate
(ESR) was performed according to the Westergreen method,
and high levels were defined as .20 mm/1
st hour. High
lactic dehydrogenase (LDH) and high uric acid levels were
evaluated according to the reference ranges based on the
patient’s age.
The leukemia patients were classified into two major
immunophenotypes, B- or T-lineage leukemia. During the
study period, all leukemia patients were treated according
to the same institutional protocol. The long-term results of
this protocol were reviewed every five years.
Statistical analysis. T h er e s u l t sa r ep r e s e n t e da st h e
median (range) or mean ¡ standard deviation for continuous
variables and as a number (%) for categorical variables. The
data were compared using the Mann-Whitney test for
continuous variables to evaluate differences between
leukemia and SoJIA patients. For categorical variables, the
differences were assessed using Fisher’s exact test. A logistic
regression analysis (Backward Stepwise) was performed to
identify the initial clinical and laboratory features that
distinguish leukemia from SoJIA patients. The overall survival
was analyzed by theKaplan-Meiermethod, and survival curves
were compared by the log-rank test in leukemia patients with
and without limb pain as well as in the overall group of 190
leukemia patients vs. leukemia patients with limb pain (n=40).
For all statistical tests, the level of significance for independent
variables was set at 5% (p,0.05).
RESULTS
Demographic data
The median ages at disease onset and at diagnosis were
significantly higher in leukemia patients compared to SoJIA
patients [5.8 (0.5-14.2) vs. 3.8 (0.5-13.3) years, p=0.0006 and
6.1 (0.8-14.3) vs. 5 (0.9-15) years, p=0.0272; respectively]. In
contrast, the period between disease onset and diagnosis
was significantly shorter in the first group [30 days (3-240)
vs. 150 days (42-3210), p,0.0001]. No statistical differences
were observed for the female gender in both groups (38%
vs. 53%, p=0.0987). The median follow-up period for
leukemia patients was eight years (1-13), and the median
of follow-up period for SoJIA patients was 6.9 years (1-14).
Clinical features
The occurrence of clinical manifestations in leukemia
patients compared to SoJIA patients is shown in Table 1. The
frequencies of limb pain, hepatomegaly, weight loss and
hemorrhagic manifestations were significantly higher in
leukemia patients than in SoJIA patients (70% vs. 1%,
p,0.0001; 54% vs. 32%, p=0.0075; 30% vs. 8%, p=0.0005 and
9% vs. 0%, p=0.0053; respectively).
The frequencies of arthritis, fever, adenomegaly, rheuma-
toid rash and pericarditis were significantly lower in
leukemia patients than in SoJIA patients (25% vs. 100%,
p,0.0001; 68% vs. 100%, p,0.0001; 21% vs. 46%, p=0.002 and
0% vs. 69%, p,0.0001; 0% vs. 16%, p=0.0006; respectively).
No differenceswere observedinthefrequenciesof arthralgia,
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(Table 1).
Laboratory alterations
The median hemoglobin, white blood cell count, neutro-
phil count, and platelet counts were significantly lower in
leukemia patients than in SoJIA patients (7 g/dl vs. 9.7
g/dl, p,0.0001; 4.6610
3/mm
3 vs. 12.3610
3/mm
3, p,0.0001;
0.8610
3/mm
3 vs. 7.3610
3/mm
3, p,0.0001 and 56.5610
3/
mm
3 vs. 490610
3/mm
3, p,0.0001). Conversely, the median
LDH level was significantly higher in leukemia patients
than in SoJIA patients (822.5 mg/dl vs. 305 mg/dl,
p,0.0001). No differences were observed in the median
uric acid levels for the two groups (Table 2).
The percentages of anemia, leukopenia, neutropenia,
thrombocytopenia, and high LDH levels were statistically
higher in leukemia patients than in SoJIA patients (88% vs.
57%, p,0.0001; 39% vs. 1%, p,0.0001; 60% vs. 1%, p,0.0001;
77% vs. 1%, p,0.0001 and 56% vs. 14%, p,0.0001;
respectively). In contrast, the frequencies of leukocytosis
and thrombocytosis were significantly lower in leukemia
patients than in SoJIA patients (17% vs. 54%, p,0.0001 and
2% vs. 68%, p,0.0001; respectively), whereas the levels of
uric acid were similarly high in both groups (Table 3).
Leukemia patients
The distributions of immunophenotypes (B- and T-
lineages) were similar in leukemia patients with limb pain
compared tothosewithoutlimbpain(98%vs.88%,p=0.2and
2% vs. 12%, p=0.2; respectively). These immunophenotypes
were also similar in the overall group of patients (n=190)
compared to leukemia patients with limb pain (92% vs. 98%,
p=0.3189 and 8% vs. 2%, p=0.3189; respectively).
The percentage of high-risk patients was similar in
leukemia patients with limb pain compared to those
without limb pain (28% vs. 29%, p=1.0). In addition, the
percentage of high-risk patients was also similar in the
overall group of patients compared to leukemia patients
with limb pain (41% vs. 28%, p=0.1527).
Multivariate analysis
Logistic regression analysis was performed by including
the following 10 independent variables that presented a level
of statistical significance of #20% in the univariate analyses:
limb pain, hepatomegaly, splenomegaly, weight loss, hemor-
rhagic manifestations, anemia, leukopenia, neutropenia,
thrombocytopenia and high LDH levels. The choice of the
variables included in this model was performed according to
the clinical plausibility for a leukemia diagnosis. Only limb
pain (OR=553; 95% CI=46.48-6580.42; p,0.0001) and
thrombocytopenia (OR=754.13; 95% CI=64.57-8806.72;
p,0.0001) remained independent risk factors that distin-
guished leukemia from SoJIA patients. The R2 of the
Nagelkerke test was 0.91 (Table 4).
Kaplan-Meier survival curves
The Kaplan-Meier overall survival curves were similar in
leukemia patients with and without limb pain (p=0.8322;
Figure 1). The survival percentage of leukemia patients with
limb pain six years after disease onset was 77%. The
survival percentage of leukemia patients without limb pain
five years after disease onset was 76%.
The overall Kaplan-Meier survival curves were also
similar in the overall group of 190 leukemia patients and
leukemia patients with limb pain (p=0.4875; Figure 2). The
survival percentage of the overall group of leukemia
patients six years after disease onset was 83%, and the
survival percentage of leukemia patients with limb pain six
years after the disease onset was 77%.
DISCUSSION
To our knowledge, this is the first study to evaluate the
largest series of children and adolescents with leukemia and
remarkable musculoskeletal manifestations and compare
these patients to those with SoJIA followed in a tertiary
pediatric university hospital. The results clearly showed
that limb pain and thrombocytopenia discriminate leukemia
from SoJIA patients at disease onset.
One of the most significant advantages of the present
study was a systematic evaluation by the same team of
Table 1 - Initial clinical manifestations in acute
lymphoblastic leukemia patients vs. systemic-onset
juvenile idiopathic arthritis patients.
Variables
LEUKEMIA
(n=57)
SoJIA
(n=102) p-value
Arthralgia 40 (70) 75 (73) 0.7128
Arthritis 14 (25) 102 (100) ,0.0001
Limb pain 40 (70) 1 (1) ,0.0001
Nighttime pain 2 (3) 2 (2) 0.6183
Fever 39 (68) 102 (100) ,0.0001
Hepatomegaly 31 (54) 33 (32) 0.0075
Splenomegaly 26 (46) 31 (30) 0.0602
Adenomegaly 12 (21) 47 (46) 0.002
Weight loss 17 (30) 8 (8) 0.0005
Hemorrhagic manifestations 5 (9) 0 (0) 0.0053
Rheumatoid rash 0 (0) 70 (69) ,0.0001
Pericarditis 0 (0) 16 (16) 0.0006
Myocarditis 0 (0) 8 (8) 0.0513
Values expressed in n (%).
Table 2 - Initial laboratory alterations in acute lymphoblastic leukemia patients vs. systemic-onset juvenile idiopathic
arthritis patients.
Variables
LEUKEMIA
(n=57) SoJIA (n=102) p-value
Hemoglobin (g/dl) 7 (3.1–11.3) 9.7 (5.4–15.5) ,0.0001
WBC (x10
3/mm
3) 4.6 (0.5–80) 12.3 (3.1–71.8) ,0.0001
Neutrophils count (x10
3/mm
3) 0.8 (0–15.6) 7.3 (0.7–69.7) ,0.0001
Platelets count (x10
3/mm
3) 56.5 (12.8–499) 490 (70–1200) ,0.0001
LDH (mg/dl) 822.5 (167–7900) 305 (13–4486) ,0.0001
Uric acid (mg/dl) 4.1 (1.3–14.4) 3.7 (0–6.1) 0.2209
Values expressed in median (range), WBC - white blood cell count, LDH - lactic dehydrogenase.
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1667pediatric rheumatologists and oncologists, with the exclu-
sion of patients treated with glucocorticosteroids. In fact,
this treatment may delay a malignancy diagnosis and
reduce the subsequent response to chemotherapy.
15
Moreover, not all leukemia patients had blasts in their
peripheral blood when they were assessed.
Conversely, our study was retrospective in nature and
included evaluations of peripheral blood smear abnormal-
ities, acute phase reaction, LDH and uric acid levels. In
particular, the last two examinations were not collected in
all patients; however, missing values have also been an
issue in others studies.
9,11
Leukemia is the most common pediatric cancer in the
United States
1 and Brazil.
16 The disease can present with
musculoskeletal findings mimicking rheumatic diseases,
including JIA,
17-23 rheumatic fever,
5 juvenile systemic lupus
erythematosus, and pediatric vasculitis,
6,9 as reported by
our pediatric rheumatology and oncology services.
7 The
initial presentation of pediatric leukemia consists of various
osteoarticular signals and symptoms, including arthralgia,
arthritis and limb pain, which may cause nighttime
wakening.
6-11,17-20
In addition, JIA includes seven different subtypes, arthritis
persisting for more than six weeks and a disease onset before
theageof 16.
14 SoJIAisa particular andinfrequent subtype of
JIA and is very similar to adult-onset Still’s disease
24 with a
specific clinical diagnosis and cytokine profile, as previously
described by our group.
25,26 Children and adolescents with
SoJIA have prominent extra-articular manifestations and a
significant elevation in acute phase reactants.
13
The differential diagnosis of suspected SoJIA may be very
difficult, particularly at disease onset, when the patient may
have only systemic manifestations without arthritis.
Therefore, the possibility of leukemia should be always
considered, as patients with SoJIA could have a longer
period between disease onset and diagnosis, as observed
here. Moreover, these two diseases have an impact on
morbidity and health-related quality of life.
27
In the univariate analysis, limb pain, hepatomegaly,
weight loss, and hemorrhagic manifestations were
predominantly observed in our leukemia patients compared
to SoJIA patients, consistent with previous observations.
7-9
We also found higher levels of anemia, leukopenia,
neutropenia, thrombocytopenia, and LDH in our acute
lymphoblastic leukemia patients, similar to the findings in
other studies.
5-7,10 Interestingly, Wallendal et al
20 showed
Table 4 - Logistic regression analysis to evaluate risk
factors distinguishing acute lymphoblastic leukemia from
systemic-onset juvenile idiopathic arthritis patients.
Independent
variable OR 95% CI R2 p-value
Limb pain 553 46.48-6580.42 0.91 ,0.0001
Thrombocytopenia 754.13 64.57-8806.72 ,0.0001
OR - odds ratio, CI – confidence interval, R2 - R2 of Nagelkerke test.
Figure 1 - The Kaplan-Meier overall survival curves between
leukemia patients without (n = 17) and with limb pain (n=40)
(p=0.8322).
Figure 2 - The Kaplan-Meier overall survival curves between the
whole group of leukemia patients (n=190) and leukemia
patients with limb pain (n=40) (p=0.4875).
Table 3 - Initial laboratory alterations in acute
lymphoblastic leukemia patients vs. systemic-onset
juvenile idiopathic arthritis patients.
Variables
LEUKEMIA
(n=57) N/n (%)
SoJIA
(n=102) N/n (%) p-value
Anemia 50/57 58/102 ,0.0001
(,10 g/dl) (88) (57)
Leukopenia 22/57 1/102 ,0.0001
(,4.000/mm
3) (39) (1)
Leukocytosis 10/57 55/102 ,0.0001
(.12.000/mm
3) (17) (54)
Neutropenia 34/57 1/102 ,0.0001
(,1.000/mm
3) (60) (1)
Thrombocytopenia 44/57 1/102 ,0.0001
(,150.000/mm
3) (77) (1)
Thrombocytosis 1/57 69/102 ,0.0001
(.400.000/mm
3) (2) (68)
High LDH 32/57 6/43 ,0.0001
(mg/dl) * (56) (14)
High Uric acid 19/57 3/11 0.73
(mg/dl) * (33) (27)
LDH - lactic dehydrogenase,
*reference range based on age.
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patients, including eight patients with leukemia.
Remarkably, we found that limb pain and thrombocyto-
penia differentiated leukemia from SoJIA patients. The
logistic regression revealed a wide confidence interval;
however, the minimum values of these confidence intervals
for both of the independent variables were high enough to
be considered. Importantly, the elevated R2 value of the
Nagelkerke test showed that the mathematical model of this
multivariate analysis was well adjusted to explain this
occurrence, indicating that these two independent variables
were associated with leukemia in 91% of our patients.
Of note, Jones et al
11 showed that the three most
important predictive factors for a pediatric leukemia
diagnosis were leukopenia, thrombocytopenia, and a
history of nighttime pain. In this multicenter study, the
authors included the three most frequent JIA subtypes
(pauciarticular, polyarticular, and systemic).
In the present study, arthritis and other extra-articular
manifestations such as fever, adenomegaly, rheumatoid
rash, and pericarditis were predominantly observed in
SoJIA patients. Likewise, leukocytosis and thrombocytosis
were frequently seen in the patients with this pediatric
rheumatic disease and could distinguish them from
leukemia patients. The presence of bicytopenia or pancyto-
penia should also exclude MAS, which is a potential life-
threatening complication of SoJIA
13,24,26,28 and can rarely be
one of the first manifestations of this disease. None of SoJIA
patients had MAS at disease onset, and none died during
the evaluation.
In conclusion, the present study emphasizes the impor-
tance of investigating leukemia in children and adolescents
that present with musculoskeletal manifestations, and in
particular, those with limb pain and thrombocytopenia.
These symptoms may mimic SoJIA, even in the absence of
blasts on the peripheral blood smear.
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